
Autolus Therapeutics plc AUTL
€ 1.37
0.0%
Quartalsbericht 2026-Q1
hinzugefügt 14.05.2026
Autolus Therapeutics plc Langfristige Verbindlichkeiten 2011-2026 | AUTL
Langfristige Verbindlichkeiten Jährlich Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 50.6 M | 23.7 M | 601 K | 1.03 M | 758 K | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 50.6 M | 601 K | 15.3 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 16.88 | -2.43 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
31.3 M | $ 2.79 | -8.09 % | $ 261 M | ||
|
Coherus BioSciences
CHRS
|
189 M | $ 1.6 | -2.15 % | $ 187 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 7.56 | -3.45 % | $ 207 M | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Exelixis
EXEL
|
63.6 M | $ 50.41 | -1.36 % | $ 13.7 B | ||
|
Fortress Biotech
FBIO
|
83.9 M | $ 2.43 | 5.65 % | $ 67.8 M | ||
|
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
10.5 M | $ 23.1 | -3.57 % | $ 299 M | ||
|
Fennec Pharmaceuticals
FENC
|
24.6 M | $ 9.76 | 5.63 % | $ 279 M | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
BioNTech SE
BNTX
|
622 M | $ 89.16 | -3.08 % | $ 21.5 B | ||
|
Galectin Therapeutics
GALT
|
52 K | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
29.2 B | $ 130.07 | -1.51 % | $ 162 B | ||
|
Genmab A/S
GMAB
|
769 M | $ 26.8 | -0.37 % | $ 1.73 B | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.41 | -2.25 % | $ 5.61 M | ||
|
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Grifols, S.A.
GRFS
|
10.6 B | $ 7.74 | -0.64 % | $ 5.26 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.72 | -1.05 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Eton Pharmaceuticals
ETON
|
4.56 M | $ 29.69 | -0.92 % | $ 799 M | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 21.51 | -0.3 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M |